Orforglipron (Foundayo)
The first FDA-approved small-molecule oral GLP-1 for chronic weight management—important for access and convenience, but not a muscle-preservation therapy.
Signal summary
Orforglipron changed the obesity-treatment landscape in 2026 by bringing a non-peptide GLP-1 weight-management therapy to a once-daily pill without the food and water restrictions associated with oral semaglutide.
Study details
Doses studied — not a dosing recommendation. Regimens belong to the named study, formulation and population.
ATTAIN-1 phase 3 trial
- Population
- 3,127 randomized adults with obesity without diabetes.
- Doses and administration studied
- Trial formulation: oral orforglipron 6, 12 or 36 mg once daily versus placebo, with escalation. Trial milligrams must not be substituted for current commercial-label dosing.
- Duration
- 72 weeks
- Reported finding / status
- Treatment-regimen weight changes: -7.5%, -8.4% and -11.2% across the three doses versus -2.1% placebo.
- Interpretation and limitations
- Gastrointestinal adverse effects were common. Weight efficacy does not demonstrate selective muscle preservation.
Source tier B · Read the original study or record
Outcome Evidence Strength
Weight: pivotal randomized trial plus regulatory evidence. Other scores: direct fat, lean and function benefits are not established by the cited primary report.
What is actually established?
- FDA approved Foundayo (orforglipron) on April 1, 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity.
- FDA describes it as a novel oral small-molecule GLP-1 receptor agonist.
- Pivotal trials demonstrated clinically meaningful weight reduction versus placebo.
What is not established?
- An obesity approval is not evidence of selective fat loss.
- Comparative evidence for lean-mass preservation versus tirzepatide, semaglutide or emerging muscle-directed combinations remains limited.
- Individual response, tolerability and appropriateness still require clinical assessment.
Still being studied
Direct body-composition outcomes, lean-mass changes and comparisons with injectable incretin therapies.
Best human evidence at a glance
| Evidence | Population | Comparator & duration | Outcome measured | Evidence state |
|---|---|---|---|---|
| FDA multidisciplinary review | Adults with obesity or overweight and at least one weight-related comorbidity | Two randomized, double-blind, placebo-controlled trials · 72 weeks | Weight-management efficacy and benefit-risk assessment | Regulatory / official Approval does not establish selective fat loss or muscle preservation. |
Safety evidence context
Regulatory review and approved labeling provide the primary safety context. This page does not replace the current official label or individualized clinical assessment.
Interpretation boundary
Approval supports the labeled indication; it does not establish every composition or muscle-related claim.
What changed: Clarified indication-specific approval, separated weight evidence from composition claims and added source provenance.
Evidence sources
FDA approval and indication, April 1, 2026
Regulatory efficacy and benefit-risk review